Repare Therapeutics saw the highest growth of 3.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 3.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Repare Therapeutics’s patent filings and grants. Buy the databook here.
Repare Therapeutics has been focused on protecting inventions in European Patent Office(EPO) with four publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 25% of filings. The European Patent Office(EPO), United States(US), World Intellectual Property Organization(WIPO), and Australia(AU) patent Office are among the top ten patent offices where Repare Therapeutics is filings its patents..
Roche could be the strongest competitor for Repare Therapeutics
Patents related to rare diseases lead Repare Therapeutics's portfolio
Repare Therapeutics has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Melanoma related patents lead Repare Therapeutics portfolio followed by breast cancer, and adenocarcinoma
Repare Therapeutics has highest number of patents in melanoma followed by breast cancer, adenocarcinoma, bladder carcinoma, and sarcomas.
For comprehensive analysis of Repare Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.